基石药业-B(02616.HK)遭执行董事胡正国减持22.3万股

Group 1 - The core point of the news is that Hu Zhengguo, an executive director of Basestone Pharmaceuticals-B (02616.HK), reduced his shareholding by selling 223,000 shares at an average price of HKD 12.007 per share, totaling approximately HKD 2.678 million [1] - After the sale, Hu Zhengguo's total shareholding decreased to 2.471 million shares, resulting in a reduction of his ownership percentage from 0.18% to 0.17% [1]